CX Partners-backed Veeda Clinical Research gets Sebi nod for its Rs 832 crore IPO equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
CX Partners-backed Veeda Clinical Research files for IPO to raise 831 cr equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk drugs firm Supriya Lifesciences, drug formulations firm Windlass Biotech, Bain Capital-backed Emcure Pharma and CX Partners-funded Veeda Clinical Research. According to investment-bankers, they are planning to mop up over Rs 7,000 crore in primary share sales.
Veeda Clinical Research raises funds from Sabre Partners and HNI investors thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
The proposed flotation, if successful, would be the largest such offer beating Coal India’s Rs 15,200 crore-IPO in 2010, the country’s largest till date